The FDA has updated the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone to include a “restricted access and distribution program.”
Clinicians and patients now must enroll in the Avandia-Rosiglitazone Medicines Access Program to prescribe and receive rosiglitazone.
The global trial that has just resoundingly proved that the partners of people on Aids drugs are almost completely protected from being infected with HIV themselves is extraordinarily good news. I wrote a story about it on Thursday night.
And the more you think about it, the better this news seems. On Thursday, I also wrote of the fears of women in Uganda that they will face violence and criminalisation as a result of a bill now being debated in parliament that would force them to tell their partner if they test positive for HIV – or oblige the health worker administering the test to tell the man instead. The article was shortened and incorporated into a general story on Uganda. B
Please take a moment to asking the Midwestern Congressional Delegation (senators and representatives from Midwestern states) to work for increased funding for the AIDS Drug Assistance Program (ADAP). You may sign the letter as an individual or on behalf of an organization; simply fill out the form at the bottom of the screen.
Dear Midwestern Congressional Delegation,
As HIV/AIDS organizations and advocates within the Midwest, we work on the front lines to ensure people living with HIV/AIDS in our states can access the services and treatment they need to stay healthy, work, and take care of themselves and their families.
A 10-year study on early HIV treatment has been stopped prematurely after a monitoring board found convincing evidence that it “can have a major impact on reducing HIV transmission,” said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, in an NIH announcement Thursday.
Called HPTN 052, the international study was conducted primarily among some 1800 heterosexual couples. One partner in each couple was uninfected at entry. Infected partners were randomized either to immediate treatment with a three-drug antiretroviral regimen or to deferred treatment (until CD4 counts fell below 250 per cubic millimeter or an AIDS-related event occurred).
There were 28 new infections linked to partners, 27 of which occurred among the deferred-treatment group, giving a relative reduction in transmission of 96%.
Dr.
